Rakuten Investment Management Inc. Buys Shares of 27,459 IQVIA Holdings Inc. $IQV

Rakuten Investment Management Inc. purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 27,459 shares of the medical research company’s stock, valued at approximately $5,307,000.

Other large investors have also made changes to their positions in the company. International Assets Investment Management LLC acquired a new position in IQVIA during the fourth quarter worth about $27,000. Compass Financial Management LLC acquired a new stake in shares of IQVIA during the 2nd quarter valued at approximately $27,000. Gilpin Wealth Management LLC purchased a new stake in shares of IQVIA during the 4th quarter worth approximately $27,000. CrossGen Wealth LLC purchased a new stake in shares of IQVIA during the 4th quarter worth approximately $28,000. Finally, Activest Wealth Management raised its holdings in IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on IQV shares. TD Cowen upped their target price on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. William Blair raised shares of IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a report on Thursday, July 9th. Mizuho upped their price target on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $241.88.

Insiders Place Their Bets

In other IQVIA news, insider W Richard Staub sold 5,500 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the transaction, the insider owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This represents a 29.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider owned 1,348 shares in the company, valued at $317,143.96. This trade represents a 57.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 12,913 shares of company stock worth $3,098,793. 1.70% of the stock is owned by company insiders.

IQVIA Price Performance

IQVIA stock opened at $260.48 on Friday. The stock has a market capitalization of $42.88 billion, a P/E ratio of 32.32, a P/E/G ratio of 2.24 and a beta of 1.18. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $265.25. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The firm’s 50-day moving average is $222.14 and its two-hundred day moving average is $189.62.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the previous year, the business posted $2.81 earnings per share. The company’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has authorized a stock buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.